Medical device company TransEnterix is on its way to securing another $2.5 million in financing.
The Research Triangle Park company has raised just shy of $2 million in funding, a mix of debt, options and warrants, according to securities filings. A total of nine investors so far have participated in the offering, which started on Aug. 5.
TransEnterix has already commercialized a minimally-invasive surgical system. The SPIDER surgical system requires only a small incision in the belly button to give surgeons access to the abdomen to perform a variety of procedures. The company is now testing a new system, SurgiBot, a surgical system that brings robotic capabilities to TransEnterix’s approach to surgery; in contrast, the SPIDER system is operated manually by a surgeon.
TransEnterix in June said the company expects SurgiBot to be ready for regulatory review by the Food and Drug Administration next year.
